Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ZNF529 antisense RNA 1 (ZNF529-AS1)
- Target
- ZNF529-AS1
- Molecular classification
- Antisense long non-coding RNA, lncRNA
01
Overview
ZNF529 antisense RNA 1 (ZNF529-AS1) is a long non-coding RNA transcribed from the antisense strand of the ZNF529 gene. It is highly expressed in certain cancers, particularly hepatocellular carcinoma (HCC), where it is closely associated with pathological stage, tumour grade, and poor prognosis. Functionally, ZNF529-AS1 promotes the invasion and migration of HCC cells and inhibits immune cell-mediated killing of tumour cells, likely contributing to immune evasion and tumour progression. Mechanistically, ZNF529-AS1 regulates the expression of downstream targets such as FBXO31, and its activity is linked to the modulation of immune checkpoint molecules (including CD80, PD-1, and CD276). These functions position ZNF529-AS1 as a candidate prognostic biomarker and a potential therapeutic target in HCC and other cancers; its knockdown may improve sensitivity to targeted drug therapies and enhance immunotherapy response.
- Other names
- ZNF529-AS1ZNF529 antisense RNA 1
02
Mechanism of action
Influences invasion and migration by regulating FBXO31 expression; inhibits killing effect of immune cells on HCC; affects immune checkpoint molecule expression (CD80, PD-1, CD276)
03
Biological functions
Cell invasionCell migrationImmune modulationTumor progressionRegulation of gene expression
04
Disease associations
CancerHepatocellular carcinomaOther tumours
05
Safety considerations
Not explicitly reportedrelevant concerns may relate to tumour progression and immune suppression if targeted
06
Biomarkers
Prognostic marker for hepatocellular carcinomahigh ZNF529-AS1 expression linked to poor prognosis
Beyond the preview
Go deeper on ZNF529 antisense RNA 1 (ZNF529-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZNF529 antisense RNA 1 (ZNF529-AS1).